Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=192 Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Primary: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs — 34.4; 30.3; 43.8; 31.3 percentage of…
Phase 2 N=42 Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
Plasma Cell Myeloma · Residual Disease
Primary: Percentage of Participants With MRD Negativity — 18; 31 percentage of participants
Phase 2 N=19 Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Breast Cancer · HER2-negative Breast Cancer · ER Positive Breast Cancer
Primary: Percentage Change in Ki67 — -0.64; -0.68; -0.63; -0.46 percentage
Phase 2 N=13 Qbrexza Cloths for Hyperhidrosis of Amputation Sites
Amputation · Hyperhidrosis
Primary: ASDD-m Sweat Severity Score — 1.2; 3.6 score on a scale of 0-10
Phase 2 N=73 A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Major Depressive Disorder · Menopause · Perimenopause
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 26.2; 27.0; 15.7; 15.2 units on a scale — p=0.29
Phase 2 N=26 Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · PSA Progression
Primary: Proportion of Participants With Undetectable Serum Prostate-specific Antigen (PSA) — 0; 0.308 proportion of participants
Phase 2 N=78 Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
Appendix Carcinoma · Colon Carcinoma · Esophageal Carcinoma
Primary: Change in Severity of Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline to 3 Months — 5.9; 9.1; 1.9; 5.7 units on a scale
Phase 2 N=73 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Liver Cirrhosis
Primary: Cumulative Number of Subjects With Any of the Components of the Composite Endpoint: >2kg Increase in Body Weight (Office-based), >2 L Increase in Total Body Water…
Phase 2 N=100 Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Breast Cancer
Primary: Incidence of Implant Failure — 8; 17; 34; 41 Number of Participants with Implant Fail
Phase 2 N=263 To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Proportion of Subjects With at Least 75% Improvement in PASI (PASI 75) — 14.0; 28.3; 23.0; 16.7 percentage of subjects — p=0.1011
Phase 2 N=213 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Advanced Cancer
Primary: Safety Related Events for Cohorts 1A, 1B and 2B. — 4; 4; 5; 6 Participants
Phase 2 N=20 Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
HIV-1-infection
Primary: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) — 95 percentage of participants
Phase 2 N=59 Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Growth Hormone Disorder · Growth Hormone Deficiency in Children
Primary: Height Velocity (HV) (cm/Year) During the First 26 Weeks of Treatment, Measured as Standing Height With Stadiometer — 11.35; 7.96; 10.92; 12.88 Centimetre per year…
Phase 2 N=149 Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease
Parkinson Disease
Primary: Changes From Baseline in Scores of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) in Subjects After 12 Weeks of…